thought call
oper trend improv next leg growth remain unclear jnj qualiti
result like eas investor concern near-term oper headwind solid
top- bottom-lin perform pharma continu
anchor portfolio initi posit sign effort turn-
around consum much laud babi re-launch
increment improv medic devic pharma fx
remicad biosimilar concerta velcad like zytiga remain
headwind increment increas guidanc reinforc view
manag thu far look howev weve model organ
growth pharma pre assumpt better
earli forecast dont think line extens life cycl
manag strategi new launch tremfya erleada could drive
much upsid given headwind note contribut
esketamin potenti launch similarli uncertain note zytiga flat y/i basi
weve model pharma organ growth could approach thu
like portfolio pipelin pharma concern growth deceler
justifi ew rate pt
pipelin updat stelara phase data uc file tremfya
trial vs cosentyx pso eclips complet expect data erleada
eu approv nmcrpc expect erleada combin zytiga
chemo-nav mcrpc data earli esketamin launch anticip
file us eu like prepar fda panel darzalex mm file
expect base maia studi
model updat given trend commentari updat model
increas revenu estim outlook
oper margin expect ep ep
figur detail
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight think outlook intact
recent success pharmaceut broader
move away defens stock less like
result share continu outperform
remicad biosimilar moder pipelin
potenti slow medic devic util full
consum stapl valuat make
could use substanti balanc sheet
acquisit fuel faster expect growth
consum margin could improv quickli
medic devic share growth could acceler
pharmceut pipelin expect may
conserv
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commer success medic devic
util deceler consum margin
expand quickli could result downward
pressur share price
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph kristen stewart cfa herebi certifi view express research report accur reflect
person view subject secur issuer refer research report part compens
directli indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
